このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

A Study to Learn About the Study Medicine Called PF-08165784 in People With PIK3CA-Mutated Advanced or Metastatic Solid Tumors

2026年11月13日 更新者:Pfizer

A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTI-TUMOR ACTIVITY OF PF-08165784 MONOTHERAPY AND COMBINATIONS IN PARTICIPANTS WITH PIK3CA-MUTATED ADVANCED OR METASTATIC SOLID TUMORS

The purpose of this study is to learn about the safety and effects of the study medicine (called PF-08165784) when given alone or together with other anti-cancer therapies. Anti-cancer therapy is a type of treatment given to stop the growth of cancer. This study also aims to find the best amount of study medication that can be given to patients.

This study is seeking participants with a specific type of breast cancer called hormone receptor-positive (HR+), HER2- negative (HER2-) breast cancer, or colorectal cancer (cancer of the colon or rectum), that has a change (mutation) in a gene called PIK3CA. The cancer must be advanced or metastatic, meaning it has spread to other parts of the body or cannot be completely removed with surgery.

All participants in this study will take the study medication (PF-08165784) as a tablet by mouth. The participant may take the medicine at the study clinic during study visits or at home. Treatment will be given in 28-day cycles and will continue for as long as the participant remains in the study. Depending on which part of the study participants are enrolled into, they will receive the study medication (PF-08165784) alone or in combination with other anti-cancer medications.

調査の概要

研究の種類

介入

入学 (推定)

268

段階

  • フェーズ 1

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • Arkansas
      • Fayetteville、Arkansas、アメリカ、72703
        • Highlands Oncology Group, PA
      • Rogers、Arkansas、アメリカ、72758
        • Highlands Oncology Group, PA
      • Springdale、Arkansas、アメリカ、72762
        • Highlands Oncology Group, PA
    • Michigan
      • Grand Rapids、Michigan、アメリカ、49546
        • START Midwest, LLC
      • San Juan、プエルトリコ、00935
        • Pan American Center for Oncology Trials, LLC- Hospital Oncológico Office

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • 18 years of age or older
  • Advanced or metastatic cancer of the breast or colon Part 1A, IB, and 1C: HR+/HER2- advanced or metastatic breast cancer with disease progression after at least 1 line of treatment with an endocrine therapy and CDK4/6 inhibitor in the advanced or metastatic setting and received no more than 1 line of prior cytotoxic and/or 1 line of prior ADC therapy in the metastatic setting Part 1D: Metastatic or advanced colorectal cancer with at least having received chemotherapy and/or targeted therapy if appropriate Part 2A: HR+/HER2- advanced or metastatic breast cancer with no prior systemic therapy or chemotherapy for advanced or metastatic disease
  • PIK3CA mutation
  • Archived tumor specimen or fresh tumor biopsy
  • Measurable disease
  • ECOG performance status 0 or 1

Exclusion Criteria:

  • Active or clinically significant dermatologic conditions
  • Active malignancy within 3 years prior to enrollment
  • Advanced/metastatic, symptomatic, visceral spread, that are at risk of life-threatening complications in the short term
  • Major surgery or radiation therapy within 3 weeks prior to study entry
  • Prior irradiation to >25% of the bone marrow
  • Active or history of pneumonitis/interstitial lung disease requiring corticosteroids
  • Unmanageable ascites
  • Prior treatment with PI3K/AKT/mTOR pathway inhibitors may be permitted in certain study cohorts and excluded in others, as specified by the study protocol.
  • Renal impairment
  • Hepatic dysfunction
  • Hematologic abnormalities
  • Uncontrolled diabetes
  • Cardiac abnormalities
  • Active or history of clinically significant GI or inflammatory GI disease
  • Other unacceptable abnormalities or prohibited therapies as defined by protocol

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:非ランダム化
  • 介入モデル:順次割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Part 1 Dose Escalation Cohort 1A

PF-08165784 monotherapy dose escalation for participants with advanced or metastatic BC at different doses of the study drug

Taken by mouth (PO)

実験的:Part 1 Dose Escalation Cohort 1B

Combination (PF-08165784 + fulvestrant) dose escalation for participants with advanced or metastatic BC, at different doses of the study drug

Selective Estrogen Receptor Degrader (SERD)

他の名前:
  • ファスロデックス

Taken by mouth (PO)

実験的:Part 1 Dose Escalation Cohort 1C

Combination (PF-08165784 + fulvestrant + atirmociclib) dose escalation for participants with advanced or metastatic BC, at different doses of the study drug

Selective Estrogen Receptor Degrader (SERD)

他の名前:
  • ファスロデックス

Taken by mouth (PO)

Selective CDK4 inhibitor

他の名前:
  • PF-07220060
実験的:Part 1 Dose Escalation Cohort 1D

Combination (PF-08165784 + cetuximab) dose escalation for participants with advanced or metastatic CRC at different doses of the study drug

Monoclonal antibody (EGFR inhibitor)

他の名前:
  • アービタックス

Taken by mouth (PO)

実験的:Part 2 Dose Optimization/Expansion Cohort 2A

Combination (PF-08165784 + letrozole + atirmociclib) dose optimization/expansion for participants with advanced or metastatic BC, at different doses of the study drug

Taken by mouth (PO)

Selective CDK4 inhibitor

他の名前:
  • PF-07220060

Nonsteroidal aromatase inhibitor

他の名前:
  • フェマラ

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Part 1 (Dose Escalation): Number of participants with Dose-Limiting Toxicities (DLT)
時間枠:Baseline up to 28 days

Any adverse events that are attributable to one, the other, or both study treatments, occurring in the DLT observation period are considered DLTs, excluding toxicities clearly due to underlying disease or extraneous causes.

Baseline up to 28 days
Part 1 (Dose Escalation): Number of participants with laboratory abnormalities
時間枠:From start of treatment up to 30 days after last dose or start of new anticancer therapy, whichever occurred first

Number of participants with laboratory test abnormalities.

From start of treatment up to 30 days after last dose or start of new anticancer therapy, whichever occurred first
Part 1 (Dose Escalation): Incidence of Adverse Events (AEs)
時間枠:From start of treatment up to 30 days after last dose or start of new anticancer therapy, whichever occurred first

An adverse event (AE) was any untoward medical occurrence in a participant who received study medication without regard to possibility of causal relationship to it.

From start of treatment up to 30 days after last dose or start of new anticancer therapy, whichever occurred first
Part 2 (Dose Expansion): Objective Response Rate (ORR)
時間枠:Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)

ORR defined as per Response Evaluation Criteria in Solid Tumors (RECIST v1.1).

Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)

二次結果の測定

結果測定
メジャーの説明
時間枠
Part 2 (Dose Expansion): Number of participants with laboratory abnormalities
時間枠:From start of treatment up to 30 days after last dose or start of new anticancer therapy, whichever occurred first

Number of participants with laboratory test abnormalities.

From start of treatment up to 30 days after last dose or start of new anticancer therapy, whichever occurred first
Part 2 (Dose Expansion): Incidence of Adverse Events (AEs)
時間枠:From start of treatment up to 30 days after last dose or start of new anticancer therapy, whichever occurred first

An adverse event (AE) was any untoward medical occurrence in a participant who received study medication without regard to possibility of causal relationship to it.

From start of treatment up to 30 days after last dose or start of new anticancer therapy, whichever occurred first
Part 1 & Part 2: Disease Control Rate (DCR) as per RECIST v1.1
時間枠:Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)

DCR is defined as the proportion of participants with CR or PR with confirmation, or Stable Disease (SD) per RECIST version 1.1.

Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)
Part 1 & Part 2: Clinical Benefit Rate (CBR) as per RECIST v1.1
時間枠:Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)

CBR is defined as the percentage of participants with a best overall response of CR or PR at any time before Progressive Disease (PD), or non-CR/non-PD or SD for at least 24 weeks from start date of treatment and prior to PD, relative to the appropriate analysis set.

Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)
Part 1 & Part 2: Duration of Response (DOR) as per RECIST v1.1
時間枠:Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)

DOR is defined as the time from first documentation of CR or PR to date of first documentation of PD or death due to any cause.

Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)
Part 1 & Part 2: Progression-Free Survival (PFS) as per RECIST v1.1
時間枠:Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)

PFS is defined as time from start date of treatment to the date of first documentation of PD or death due to any cause.

Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)
Part 1 & Part 2: Time to Response (TTR) as per RECIST v1.1
時間枠:Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)

TTR is defined as the time from start date of treatment to first documentation of CR or PR.

Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)
Part 2: Overall Survival (OS)
時間枠:Up to approximately 2 years

OS is defined as time from from start date of treatment to the date of death due to any cause

Up to approximately 2 years
Part 1: Objective Response Rate (ORR) as per Response Evaluation Criteria in Solid Tumors (RECIST v1.1)
時間枠:Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)

ORR is defined as the percentage of participants in the analysis population having a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR) according to RECIST v1.1.

Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)
Part 1: Maximum Observed Serum Concentration (Cmax) & Trough Concentration (Ctrough)
時間枠:Baseline through end of Cycle 1 (each cycle is 28 days)

Evaluate the single and multiple dose PK of PF-08165784 as monotherapy, or in combination with other anti-tumor agents.

Baseline through end of Cycle 1 (each cycle is 28 days)
Part 1: Time to Reach Maximum Observed Serum Concentration (Tmax)
時間枠:Baseline through end of Cycle 1 (each cycle is 28 days)

Evaluate the single and multiple dose PK of PF-08165784 as monotherapy, or in combination with other anti-tumor agents.

Baseline through end of Cycle 1 (each cycle is 28 days)
Part 1: Area Under the Curve (AUC) from Time Zero to Last Quantifiable Concentration (AUClast)
時間枠:Baseline through end of Cycle 1 (each cycle is 28 days)

Evaluate the single and multiple dose PK of PF-08165784 as monotherapy, or in combination with other anti-tumor agents.

Baseline through end of Cycle 1 (each cycle is 28 days)
Part 1: Effect of Food on Cmax
時間枠:Baseline through end of Cycle 1 (each cycle is 28 days)

Evaluate the effect of food on Cmax of PF-08165784 as monotherapy

Baseline through end of Cycle 1 (each cycle is 28 days)
Part 1: Effect of Food on Tmax
時間枠:Baseline through end of Cycle 1 (each cycle is 28 days)

Evaluate the effect of food on Tmax of PF-08165784 as monotherapy

Baseline through end of Cycle 1 (each cycle is 28 days)
Part 1: Effect of Food on AUClast
時間枠:Baseline through end of Cycle 1 (each cycle is 28 days)

Evaluate the effect of food on AUClast of PF-08165784 as monotherapy

Baseline through end of Cycle 1 (each cycle is 28 days)
Part 2 (Dose Expansion): Pre- and post-dose concentrations of PF-08165784
時間枠:Baseline through end of Cycle 1 (each cycle is 28 days)

Evaluate the pre- and post-dose concentrations of PF-08165784

Baseline through end of Cycle 1 (each cycle is 28 days)

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • スタディディレクター:Pfizer CT.gov Call Center、Pfizer

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年11月9日

一次修了 (推定)

2030年3月22日

研究の完了 (推定)

2032年3月21日

試験登録日

最初に提出

2026年10月20日

QC基準を満たした最初の提出物

2026年10月20日

最初の投稿 (実際)

2026年10月27日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月18日

QC基準を満たした最後の更新が送信されました

2026年11月13日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

IPD プランの説明

Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

米国で製造され、米国から輸出された製品。

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する